NICE Should Revise Assessment Process After Relenza Review, ABPI Says
Executive Summary
The Association of the British Pharmaceutical Industry is proposing an alternative procedure for the U.K.' s National Institute of Clinical Excellence to follow in its new drug assessments, following NICE's Oct. 8 decision to recommend against prescribing Glaxo Wellcome's Relenza for the 1999 flu season.You may also be interested in...
Tamiflu DTC Ads Should Encourage Flu Vaccination, FDA's Jolson Suggests
Tamiflu DTC Ads Should Encourage Flu Vaccination, FDA's Jolson Suggests
WellPoint Hopes To Curb Relenza Costs By Pushing Flu Vaccination
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: